Results 1 to 10 of about 10,723 (119)

The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay

Clinical and Applied Thrombosis/Hemostasis, 2021
The FVIII activity in patients treated with several extended half-life FVIII (EHL-FVIII) agents different when various activated partial thromboplastin time (APTT) reagents were used.
Kohshi Ohishi, Hideo Wada, Takeshi Matsumoto   +2 more
exaly   +2 more sources

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner

Frontiers in Immunology, 2023
IntroductionSoluble antigens complexed with immunoglobulin G (IgG) antibodies can induce robust adaptive immune responses in vitro and in animal models of disease. Factor VIII immune complexes (FVIII-ICs) have been detected in individuals with hemophilia
Glaivy Batsuli, Glaivy Batsuli, Jasmine Ito, Jasmine Ito, Elizabeth S. York, Elizabeth S. York, Courtney Cox, Courtney Cox, Wallace Baldwin, Wallace Baldwin, Surinder Gill, Surinder Gill, Pete Lollar, Pete Lollar, Shannon L. Meeks, Shannon L. Meeks   +15 more
doaj   +1 more source

Assessment of FVIII, D-dimer, S. ferritin, and lactate dehydrogenase in hospitalized patients with 2019 coronavirus disease

Iraqi Journal of Hematology, 2021
BACKGROUND: Corona virus disease 2019 (COVID-19) is a coronavirus that can produce a variety of symptoms, ranging from asymptomatic carrier status to severe respiratory failure, multiple organ dysfunction, and death, it might be associated with ...
Enaam Muhsin Hameed Al-Taie, Hind Shaker Al-Mamoori   +1 more
doaj   +1 more source

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells

Frontiers in Immunology, 2022
Background and aimsHemophilia A is a severe bleeding disorder caused by the deficiency of functionally active coagulation factor VIII (FVIII). The induction of neutralizing anti-drug antibodies is a major complication in the treatment of hemophilia A ...
Christian Lubich, Christian Lubich, Katharina Nora Steinitz, Brigitte Hoelbl, Thomas Prenninger, Pauline Maria van Helden, Markus Weiller, Birgit Maria Reipert, Birgit Maria Reipert   +8 more
doaj   +1 more source

In Silico Study of Correlation between Missense Variations of F8 Gene and Inhibitor Formation in Severe Hemophilia A

Turkish Journal of Hematology, 2020
Objective: Deleterious substitutions of the F8 gene are responsible for causing hemophilia A, which is an inherited bleeding disorder resulting from reduced or absent activity of the coagulant protein factor VIII (FVIII).
Mostefa Fodil, Faouzia Zemani
doaj   +1 more source

Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency

Molecular Therapy: Methods & Clinical Development, 2020
One important limitation for achieving therapeutic expression of human factor VIII (FVIII) in hemophilia A gene therapy is inefficient secretion of the FVIII protein. Substitution of five amino acids in the A1 domain of human FVIII with the corresponding
Wenjing Cao, Biao Dong, Franziska Horling, Jenni A. Firrman, Johannes Lengler, Matthias Klugmann, Maurus de la Rosa, Wenman Wu, Qizhao Wang, Hongying Wei, Andrea R. Moore, Sean A. Roberts, Carmen J. Booth, Werner Hoellriegl, Dong Li, Barbara Konkle, Carol Miao, Birgit M. Reipert, Friedrich Scheiflinger, Hanspeter Rottensteiner, Weidong Xiao   +20 more
doaj   +1 more source

Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody. [PDF]

PLoS ONE, 2015
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region.
Jasper C Lin, Ruth A Ettinger, Jason T Schuman, Ai-Hong Zhang, Muhammad Wamiq-Adhami, Phuong-Cac T Nguyen, Shelley M Nakaya-Fletcher, Komal Puranik, Arthur R Thompson, Kathleen P Pratt   +9 more
doaj   +1 more source

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A

Turkish Journal of Hematology, 2023
Objective: Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency of plasma coagulation factor VIII (FVIII), and it accounts for about 80%-85% of all cases of hemophilia.
Cansu Hemşinlioğlu, Elif Sibel Aslan, Cihan Tastan, Didem Çakırsoy, Raife Dilek Turan, Utku Seyis, Muhammer Elek, Gözde Sır Karakuş, Ömür Selin Günaydın, Selen Abanuz, Derya Dilek Kançağı, Bulut Yurtsever, Koray Yalçın, Murat Kasap, Ercüment Ovalı   +14 more
doaj   +1 more source

The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression

Blood Advances, 2020
: Previous studies have shown that platelet-specific factor VIII (FVIII) expression (2bF8) restores hemostasis and induces immune tolerance in hemophilia A (HA) mice even with preexisting inhibitors.
Qizhen Shi, Jeremy G. Mattson, Scot A. Fahs, Aron M. Geurts, Hartmut Weiler, Robert R. Montgomery   +5 more
doaj   +1 more source

Selective human factor VIII activity measurement after analytical in‐line purification

Research and Practice in Thrombosis and Haemostasis, 2022
Background It is essential to measure the activity of factor VIII (FVIII) throughout the life cycle of a coagulation FVIII concentrate. Such measurement in nonclinical pharmacokinetic studies is potentially biased by the presence of endogenous nonhuman ...
Andrea Engelmaier, Gerald Schrenk, Manfred Billwein, Herbert Gritsch, Christoph Zlabinger, Alfred Weber   +5 more
doaj   +1 more source